Washington, D.C.’s medical cannabis industry is facing a pivotal moment as Mayor Muriel Bowser’s proposed fiscal year 2027 budget includes a significant increase in taxes on medical marijuana sales. The proposal, designed to help address a budget shortfall exceeding $1 billion, would raise the District’s medical cannabis sales tax from 6% to 10% – an increase of more than 70%.
While city officials project the move could generate millions in additional revenue for public services, cannabis operators, patients, and industry advocates warn that the tax hike could destabilize an already fragile market and drive consumers back to unregulated sources.
Why D.C. Wants to Raise Medical Cannabis Taxes
According to the mayor’s office, the proposed increase would align the tax rate on medical cannabis with the District’s tax rate on off-premise alcohol sales. Officials estimate the change would contribute approximately $1.5 million to the city’s general fund in fiscal year 2027 and more than $6 million over the life of the budget plan.
Those funds would be directed toward essential government services, including healthcare and education. However, unlike many other regulated industries, cannabis businesses argue that little of the revenue generated from cannabis sales is reinvested back into the industry itself.
The proposal has become particularly controversial because no other business sector is facing a comparable sales tax increase under the current budget plan.
Industry Operators Say the Market Is Already Under Pressure
D.C.’s medical cannabis market has undergone a dramatic transformation over the past several years. Following the Medical Cannabis Amendment Act of 2022, the city expanded licensing opportunities, streamlined patient registration, and encouraged formerly unlicensed cannabis retailers to transition into the regulated market.
While these reforms successfully expanded legal access, they also led to a rapid increase in the number of dispensaries operating throughout the District.
As a result, operators say the market has become oversaturated.
Although D.C. recently recorded its highest monthly medical cannabis sales on record, revenue is now spread across significantly more businesses. Average revenue per dispensary has declined as competition intensifies, leaving many operators with increasingly thin margins.
Industry leaders argue that adding another tax burden at this stage could threaten the survival of many businesses that are only beginning to establish themselves in the regulated market.
Patients Could Feel the Impact
One of the most common concerns raised by industry stakeholders is the effect the tax increase could have on patients.
Medical cannabis users, particularly those on fixed incomes or managing chronic conditions, are often highly sensitive to price increases. Advocates warn that higher costs at licensed dispensaries could encourage some patients to seek cheaper alternatives through the illicit market.
That concern is especially relevant in Washington, D.C., where remnants of the city’s former black market still exist despite ongoing enforcement efforts.
Industry advocates argue that regulated dispensaries provide products that undergo testing for contaminants such as mold, pesticides, and heavy metals. If patients migrate to unregulated sources, they may lose access to those consumer protections.
Competition From Neighboring States Adds Another Challenge
The proposed tax increase comes at a time when neighboring states are expanding cannabis access.
Maryland’s adult-use cannabis market continues to attract consumers from the District by offering recreational purchases without requiring participation in a medical program. Meanwhile, Maryland and Delaware do not impose sales taxes on medical cannabis, while Virginia’s medical cannabis tax rate remains lower than D.C.’s current rate.
Operators say D.C.’s comparatively lower tax burden has been one of the few competitive advantages local dispensaries still possess. Raising taxes could further reduce the District’s ability to compete with neighboring markets and retain patients.
City Council Voices Concerns
The proposal has also drawn scrutiny from members of the D.C. Council.
A recent committee report warned that increasing taxes on medical cannabis could undermine industry growth, reduce sales, and potentially lead to lower tax revenues than anticipated if consumers turn to alternative purchasing channels.
The report further emphasized concerns that cannabis businesses already face a heavier tax burden than many other industries due to federal tax restrictions that limit standard business deductions.
Council members now face the challenge of balancing the city’s budget needs with the long-term viability of the regulated cannabis industry.
What Happens Next?
The D.C. Council is scheduled to vote on the proposed budget and any amendments on June 9. The decision could have significant implications for medical cannabis operators, patients, and the future of the District’s regulated cannabis market.
As lawmakers weigh the proposal, industry stakeholders continue to argue that increasing taxes on a developing medical cannabis market may ultimately do more harm than good, both for businesses and for the patients who rely on legal access to safe cannabis products.
Whether the tax hike moves forward or is revised by the Council, the debate highlights a broader challenge facing cannabis markets nationwide: how to generate public revenue without undermining the growth and sustainability of the legal industry.
Need help navigating cannabis regulations, licensing, tax challenges, or business growth strategies? Canna Business Services provides expert consulting and operational support for cannabis operators across the industry. Contact our team today to learn how we can help your business remain compliant, competitive, and positioned for long-term success.
